Silo Pharma, Inc. (SILO) Form 10-Q — Aug 13, 2026
Silo Pharma reported a net loss of $2,479,946 for the six months ended June 30, 2026, ending the quarter with $3,277,095 in cash, $1,950,147 in short-term investments, and an accumulated deficit of $21,972,335. License fee revenue fell to $18,026 for the half and was zero in Q2, and all revenue recognition ceased effective April 1, 2026 after the UMB Master License terminated. The company effected a 1-for-15 reverse stock split on June 2, 2026, with split-adjusted trading beginning June 3, 2026, and reported 1,588,250 shares outstanding as of the August 13, 2026 filing date.
Key figures
- Revenue
- 18026
- Total Assets
- 5952023
- Cash Position
- 3277095
- Shares Outstanding
- 1588250
- Q2 2026 revenue
- 0
- Working capital
- 4647793
- Accumulated deficit
- 21972335
- Reverse split ratio
- 1-for-15
- Buyback authorization
- $1,000,000 through December 31, 2026; no shares repurchased as of June 30, 2026
- Rd expense six months
- 1311683
- Short term investments
- 1950147
- Crypto assets fair value
- 205414
- Cash in excess of fdic limits
- 2718542
- July 2026 warrant exercise price
- 6.21
- July 2026 placement price per share
- 6.452
- Sponsored research commitments fy2027
- 1129000
- Contingently returnable sublicense fee
- 703552
- July 2026 placement gross proceeds approx
- approximately $4.0 million (placement agent fee of $300,001 equals 7.5% of gross)
- July 2026 placement shares and prefunded warrants
- 619965
Price after filing
Close on the filing date to close N calendar days later (from $3.22). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.